Kolexia
Zielinski-Vogt Clémentine Pharmacien
Zielinski-Vogt Clémentine
Pharmacien
Pharmacie Blajman
Illkirch-Graffenstaden, France
20 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Bévacizumab Tamoxifène Capécitabine Inhibiteurs de l'aromatase Nonoxinol Fulvestrant Aromatase {{person.topmesh10.name}}

Collaborateurs

Voir plus
Gligorov Joseph
Gligorov Joseph
Hôpital Tenon, Paris, France
Morales Sybille
Morales Sybille
N/A, Lieu inconnu
Pivot Xavier
Pivot Xavier
Centre Paul Strauss, Strasbourg, France
Martin Alain
Martin Alain
Hôpital Jean-Minjoz, Besançon, France

Industries

Voir plus
LifeScan France SAS
1 collaboration(s)
Dernière en 2021
Boiron
1 collaboration(s)
Dernière en 2022
Biocodex
1 collaboration(s)
Dernière en 2021
Roche
1 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Abstract OT2-01-06: Phase III study of palbociclib (PD-0332991) in combination with endocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. “The PEARL study” (GEICAM/2013-02)
2016 San Antonio Breast Cancer Symposium   15 février 2017
Abstract P6-14-01: Final results of the TANIA randomized phase III trial of bevacizumab (BEV) after progression on 1st-line BEV therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium   15 février 2016
Bevacizumab in HER2 negative metastatic breast cancer
Youtube @ European Society for Medical Oncology   01 novembre 2014
Are the costs of clinical trials higher than standard of care?
Youtube @ European Society for Medical Oncology   29 septembre 2013
Ten years of tamoxifen help reduce breast cancer recurrence and death
Youtube @ European Society for Medical Oncology   13 juin 2013
OT3-01-04: TANIA: A Randomized Phase III Trial Evaluating Continued and Reintroduced Bevacizumab (BEV) in Patients Previously Treated with 1st-Line BEV for Locally Recurrent/Metastatic Breast Cancer (LR/mBC).
Thirty-Fourth Annual CTRC AACR San Antonio Breast Cancer Symposium Dec 6 10, 2011   15 décembre 2011
{{person.lastact7.name}}
{{person.lastact7.jour}}   {{person.lastact7.date}}
{{person.lastact8.name}}
{{person.lastact8.jour}}   {{person.lastact8.date}}
{{person.lastact9.name}}
{{person.lastact9.jour}}   {{person.lastact9.date}}
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}